Position in RGNX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$0
-$838,000 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
2 quarters on record
Derivatives in RGNX
reported options exposure · as of Jun 30, 2026CallValue
$1,198,000
CallShares
100,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Centiva Capital, LP holds $32,694,585 across 26 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
225,000 | $15,896,250 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
50,102 | $6,650,038 | |
| 3 | MANE |
Veradermics, Inc
|
25,817 | $3,173,941 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
5,107 | $956,438 | |
| 5 | CYTK |
Cytokinetics Inc
|
9,643 | $821,487 | |
| 6 | IDYA |
IDEAYA Biosciences, Inc.
|
21,800 | $812,486 | |
| 7 | ERAS |
Erasca, Inc.
|
34,251 | $627,478 | |
| 8 | ABVX |
Abivax S.A.
|
4,512 | $601,269 |
All Filings in RGNX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,198,000 | 100,000 | Call | Sole | 2026-08-13 | |
| 2026-03-31 | $838,000 | 100,000 | Call | Sole | 2026-05-14 | |
| 2026-03-31 | $838,000 | 100,000 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||